Literature DB >> 27724023

Coagulopathy in patients with acute pulmonary embolism: a pilot study of whole blood coagulation and markers of endothelial damage.

Per Lehnert1, Pär I Johansson2,3, Sisse R Ostrowski2, Christian H Møller1, Lia E Bang4, Peter Skov Olsen1, Jørn Carlsen4.   

Abstract

Whole blood coagulation and markers of endothelial damage were studied in patients with acute pulmonary embolism (PE), and evaluated in relation to PE severity. Twenty-five patients were enrolled prospectively each having viscoelastical analysis of whole blood done using thrombelastography (TEG) and Multiplate aggregometry. Fourteen of these patients were investigated for endothelial damage by ELISA measurements of Syndecan-1 (endothelial glycocalyx degradation), soluble endothelial Selectin (endothelial cell activation), soluble Thrombomodulin (endothelial cell injury) and Histone Complexed DNA fragments (endothelial cytotoxic histones). The mean values of TEG and Multiplate parameters were all within the reference levels, but a significant difference between patients with high and intermediate risk PE was observed for Ly30 (lytic activity) 1.5% [0-10] vs. 0.2% [0-2.2] p = .04, and ADP (platelet reactivity) 92 U [20-145] vs. 59 U [20-111] p = .03. A similar difference was indicated for functional fibrinogen 21 mm [17-29] vs. 18 mm [3-23] p = .05. Analysis of endothelial markers identified a significant difference in circulating levels between high and intermediate risk PE patients for Syndecan-1 118.6 ng/mL [76-133] vs. 36.3 ng/mL [11.8-102.9] p = .008. In conclusion, patients with acute PE had normal whole blood coagulation, but high risk PE patients had signs of increased activity of the haemostatic system and significantly increased level of endothelial glycocalyx degradation.

Entities:  

Keywords:  Acute disease; endothelial cells; platelet function tests; pulmonary embolism; risk; syndecan-1; thrombelastography

Mesh:

Substances:

Year:  2016        PMID: 27724023     DOI: 10.1080/00365513.2016.1239130

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  4 in total

Review 1.  Soluble syndecans: biomarkers for diseases and therapeutic options.

Authors:  Jessica Bertrand; Miriam Bollmann
Journal:  Br J Pharmacol       Date:  2018-07-23       Impact factor: 8.739

2.  Endothelial Extracellular Vesicles in Pulmonary Function and Disease.

Authors:  Eleftheria Letsiou; Natalie Bauer
Journal:  Curr Top Membr       Date:  2018-10-08       Impact factor: 3.049

3.  Construction of a Risk Prediction Model for Hospital-Acquired Pulmonary Embolism in Hospitalized Patients.

Authors:  Lengchen Hou; Longjun Hu; Wenxue Gao; Wenbo Sheng; Zedong Hao; Yiwei Chen; Jiyu Li
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

4.  The Relevance of Anti-PF4 Antibody Isotypes and Endogenous Glycosaminoglycans and their Relationship with Inflammatory Biomarkers in Pulmonary Embolism Patients.

Authors:  Bulent Kantarcioglu; Amir Darki; Fakiha Siddiqui; Debra Hoppensteadt; Joseph Lewis; Roland Krämer; Cafer Adiguzel; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.